Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MicroRNA-122 (miR-122) response elements are specific nucleotide sequences located within the 5' untranslated region (UTR) of the Hepatitis C Virus (HCV) genome (Jopling et al., 2005, Science). Unlike the typical role of microRNAs in suppressing gene expression, miR-122 binding to these viral response elements is essential for the stability and replication of the HCV RNA (Machlin et al., 2011, PNAS). This interaction protects the viral RNA from exonucleolytic degradation by host enzymes such as Xrn1 and facilitates the assembly of the viral translation complex (Li et al., 2013, PNAS). Because miR-122 is highly expressed in the liver and is a critical host factor for HCV, these response elements represent a unique therapeutic vulnerability. Drugs like Miravirsen (SPC3649) and RG-101 are antisense oligonucleotides designed to sequester miR-122, thereby preventing its interaction with the viral response elements and effectively suppressing viral load (Janssen et al., 2013, NEJM). This approach provides a high barrier to resistance compared to traditional direct-acting antivirals because it targets a conserved host-virus interaction. Clinical studies have demonstrated that targeting this interaction leads to prolonged suppression of viremia in patients with chronic HCV infection. However, since miR-122 also regulates host genes involved in cholesterol metabolism, its sequestration can lead to a reversible decrease in serum cholesterol levels (Rothenberg et al., 2013, Journal of Hepatology).
Sequestration of host microRNA-122 by antisense oligonucleotides to prevent its binding to viral response elements, thereby promoting viral RNA degradation and inhibiting replication.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MicroRNA-122 response element (miR-122 RE) (miR-122 RE).